Draftfcb Health creates spin-off to handle Roche business

Share this article:

Manhattan-based Area 23, an offshoot of Draftfcb Healthcare, will service several clients including Roche.

The spin-off is the second one created this year by the Interpublic Group agency, which formed Project X-Ray to handle Pfizer business, including antibiotic Zmax, migraine drug Relpax and its women's health line.

Among Area 23's existing accounts will be Roche's Phase III rheumatoid arthritis compound Actemra, US and global, and its anemia biologic Mircera, whose US patents are the subject of an ongoing legal dispute with Amgen which could limit the Roche drug to ex-US markets. (A judge agreed with Amgen this month, and the biotech said it will move to block Mircera's US commercialization.) Area 23 is already working on the overseas launches.

Other accounts include GlaxoSmithKline's Lamictal for bipolar and epilepsy, US, as well as some smaller brands from other manufacturers. The 70-person office will be headed by two creative directors, Melissa Cahill and Steve Bateman, and by Mike Guarino, managing director.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...